To pay off debt and stay open, Seres will sell microbiome pill to partner Nestlé

Ryan Cross

Senior Science Correspondent

Seres Therapeutics has signed an agreement with its commercialization partner Nestlé Health Science to sell the remaining rights to its microbiome pill and focus on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

To pay off debt and stay open, Seres will sell microbiome pill to partner Nestlé

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

To pay off debt and stay open, Seres will sell mi­cro­bio­me pill to part­ner Nestlé

Senior Science Correspondent

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

To pay off debt and stay open, Seres will sell microbiome pill to partner Nestlé